PDCD1 and colorectal carcinoma: Ongoing efforts are exploring rational combination regimens — such as dual PD-1/CTLA-4 blockade, VEGF inhibition, or radiotherapy-induced immune priming — to further enhance efficacy in MSI-H CRC (Overman et al., 2018; Chalabi et al., 2020).